Impact of PGL-I Seropositivity on the Protective Effect of BCG Vaccination among Leprosy Contacts: A Cohort Study

Although leprosy has become a neglected disease, it is an important cause of disability, and 250,000 new cases are still diagnosed worldwide every year. The current study was carried out in Brazil, where almost 40,000 new cases of leprosy are diagnosed every year. The study targeted contacts of leprosy patients, who are at the highest risk of contracting the disease. We studied 2,135 contacts who were diagnosed at the Leprosy Outpatient Clinic at the Oswaldo Cruz Foundation in Rio de Janeiro, RJ, Brazil, between 1987 and 2007. The presence of antibodies against a specific Mycobacterium leprae antigen (PGL-I) at the first examination and BCG vaccination status were evaluated. PGL-I-positive contacts had a higher risk of developing leprosy than PGL-I-negative contacts. Among the former, vaccinated contacts were at higher risk than unvaccinated contacts. Our results indicate that contact examination combined with PGL-I testing and BCG vaccination appears to justify the targeting of PGL-I-positive individuals for enhanced surveillance. Furthermore, it is highly recommended that PGL-I-positive contacts and contacts with a high familial bacterial index (i.e., the sum of results from index and co-prevalent cases), regardless of serological response, should be monitored. This group could be considered as a target for chemoprophylaxis

Fatores associados à soropositividade do teste ML Flow em pacientes e contatos de pacientes com hanseníase menores de 18 anos Factors associated with ML Flow test seropositivity in leprosy patients and household contacts under the age of 18

Estudo transversal em menores de 18 anos, sendo 115 casos novos de hanseníase e 1.011 contatos intradomiciliares. Determinaram-se as proporções da soropositividade do ML Flow e fatores associados ao teste positivo. Observou-se soropositividade em 21,7% dos pacientes e 19,7% dos contatos. Nos pacientes, a regressão logística indicou associação com baciloscopia positiva e número de lesões cutâneas maior que cinco. A análise por árvore de decisão mostrou associação com baciloscopia, classificação de Madri, número de nervos acometidos e idade. Nos contatos, as duas análises indicaram as mesmas associações: classificação do caso-índice, idade e tipo de serviço de saúde. As variáveis que explicaram melhor a soropositividade, em menores de 18 anos, são aquelas associadas à maior carga bacilar. Assim, o teste ML Flow poderia ser utilizado também na infância para ajudar na correta classificação dos pacientes para tratamento e na identificação dos contatos com maior risco de desenvolver hanseníase.<br>This article presents the results of a cross-sectional study involving 115 newly-diagnosed leprosy patients and 1,011 household contacts, all under the age of 18. Seropositivity ratios and factors associated with a positive ML Flow were determined. The test was positive in 21.7% of patients and in 19.7% of contacts. Among patients, logistic regression indicated the association of seropositivity with positive slit skin smear and having more than five skin lesions. The tree method analysis indicated associations with skin smear, Madrid classification, number of nerves affected and age. In the contact group, index case classification, age and type of health service were associated with seropositivity in both analyses. The variables that best explained seropositivity are those associated with higher bacterial load. Therefore, the ML Flow test could be used in children to aid correct classification of patients for treatment and to identify contacts at greater risk of developing leprosy

Early detection of leprosy by examination of household contacts, determination of serum anti-PGL-1 antibodies and consanguinity

A cross-sectional clinical trial in which the serum anti-phenolic glycolipid (anti-PGL-1) antibodies were analysed in household contacts (HHC) of patients with leprosy as an adjunct early leprosy diagnostic marker was conducted. The families of 83 patients underwent clinical examination and serum anti-PGL1 measurement using enzyme-linked immunosorbent assay. Of 320 HHC, 98 were contacts of lepromatous leprosy (LL), 80 were contacts of borderline lepromatous (BL), 28 were contacts of borderline (BB) leprosy, 54 were contacts of borderline tuberculoid (BT), 40 were contacts of tuberculoid (TT) and 20 were contacts of indeterminate (I) leprosy. Consanguinity with the patients was determined for 232 (72.5%) HHC. Of those 232 contacts, 183 had linear consanguinity. Forty-nine HHC had collateral consanguinity. Fifty-eight contacts (18.1%) tested positive for anti-PGL1 antibodies. The number of seropositive contacts based on the clinical forms of the index case was 17 (29.3%) for LL, 15 (25.9%) for BL, one (1.7%) for BB, 14 (24.1%) for BT, three (5.2%) for TT and eight (13.7%) for I. At the one year follow-up, two (3.4%) of these seropositive contacts had developed BT leprosy. The results of the present study indicate that the serum anti-PGL-1 IgM antibody may be useful for evaluating antigen exposure and as a tool for an early leprosy diagnosis in HHC